A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Trial Profile

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Elacestrant (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 07 Dec 2017 Results presented in a Radius Health media release.
    • 07 Dec 2017 According to a Radius Health media release, results from this trial were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
    • 06 Jun 2017 Results (n= 39, as of 25 Jan 2017) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top